The authors concluded that mTOR pathway alterations leading to reactivation of the HER2 signaling axis are important drivers of neratinib resistance in histologically distinct types of HER2-mutant cancers and that the combination of neratinib and mTORC1 inhibitors may be of clinical interest in patients with HER2-mutant cancers with mTOR pathway co-mutations [121]. Here, ERBB2 is linked to cancer.